Table 2 - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Mortality rate ratio (MRR) of cancer mortality after cancer diagnosis for current antidepressant (AD) user a and former AD user b at time of cancer diagnosis.
Source publication
[This corrects the article DOI: 10.1371/journal.pone.0138134.].
Similar publications
This descriptive report presents analyses of CPRD data, showing the proportion of antidepressant prescribing that is long-term, and visualises trends in this proportion over time.
Background
Antidepressant use is more common in people with Parkinson’s disease (PD), but it is unknown when this difference emerges.
Methods
We studied the incidence of antidepressant use in six-month periods from 10 years before to 15 years after PD diagnosis in the nationwide register-based Finnish Study on Parkinson’s disease (FINPARK). This s...
Citations
... In the "Cancer Mortality in People treated with ADs before Cancer Diagnosis" study, the one-year mortality rate increases by 32% when ADs were pursued during the cancer's disease. The mortality increases by 54% when ADs were initiated during the 4 months preceding the cancer diagnosis (in a population-based cohort study with cancer from January 2003 to December 2010 in Denmark (150,151). ...
The review states that antidepressants (ADs) increase brain-derived neurotrophic factor (BDNF) transmission concomitantly in the brain and the blood: ADs increasing BDNF synthesis in specific areas of the central nervous system (CNS) could presumably affect megakaryocyte's production of platelets. ADs increase BDNF levels in the CNS and improve mood. In the blood, ADs increase BDNF release from platelets. The hypothesis presented here is that the release of BDNF from platelets contributes to the ADs effects on neurogenesis and on tumor growth in the cancer disease. Oncological studies indicate that chemicals ADs exert an aggravating effect on the cancer disease, possibly by promoting proplatelets formation and enhancing BDNF release from platelets in the tumor.
